Photo of David G. Nathan,  MD

David G. Nathan, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2155
Fax: (617) 632-2161


david_nathan@dfci.harvard.edu

David G. Nathan, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Robert A Stranahan Distinguished Professor of Peds, Pediatrics, Harvard Medical School

Research Abstract

The pathophysiology and treatment of congential bone marrow failure and red cell syndromes.

Publications

Powered by Harvard Catalyst
  • Nathan DG. Amino acid uptake in erythropoiesis. Sci Signal 2015; 8:fs9. PubMed
  • Archer NM, Shmukler BE, Andolfo I, Vandorpe DH, Gnanasambandam R, Higgins JM, Rivera A, Fleming MD, Sachs F, Gottlieb PA, Iolascon A, Brugnara C, Alper SL, Nathan DG. Hereditary xerocytosis revisited. Am J Hematol 2014. PubMed
  • Field JJ, Nathan DG, Linden J. The role of adenosine signaling in sickle cell therapeutics. Hematol Oncol Clin North Am 2014; 28:287-99. PubMed
  • Field JJ, Nathan DG. Advances in sickle cell therapies in the hydroxyurea era. Mol Med 2014; 20 Suppl 1:S37-42. PubMed
  • Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, Sieff CA, Orkin SH, Nathan DG, Lander ES, Gazda HT. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 2012; 122:2439-43. PubMed
  • Narla A, Vlachos A, Nathan DG. Diamond blackfan anemia treatment: past, present, and future. Semin Hematol 2011; 48:117-23. PubMed
  • Field JJ, Nathan DG, Linden J. Targeting iNKT cells for the treatment of sickle cell disease. Clin Immunol 2011. PubMed
  • Sankaran VG, Nathan DG. Reversing the hemoglobin switch. N Engl J Med 2010; 363:2258-60. PubMed
  • Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am 2010; 24:1005-20. PubMed
  • Nathan DG. A life-long quest to understand and treat genetic blood disorders. Cell 2010; 143:17-20. PubMed
  • Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010; 116:687-92. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: Hepatitis C. Genome Med 2010; 2:4. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: the slow but inexorable process of medical care reform in the United States. Genome Med 2009; 1:94. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: the Obama effect redux. Genome Med 2009; 1:86. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: cholesterol and coronary artery disease. Genome Med 2009; 1:60. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: Crohn's disease. Genome Med 2010; 1:103. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases. Genome Med 2010; 1:114. PubMed
  • Rebel VI, Tanaka M, Lee JS, Hartnett S, Pulsipher M, Nathan DG, Mulligan RC, Sieff CA. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood 1999; 93:2217-24. PubMed
  • Nathan DG, Weatherall DJ. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 1998; 339:1711-2; author reply 1713. PubMed
  • Janov AJ, Leong T, Nathan DG, Guinan EC. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore) 1996; 75:77-8. PubMed
  • Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331:574-8. PubMed
  • Guinan EC, Lopez KD, Huhn RD, Felser JM, Nathan DG. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with fanconi anemia. J Pediatr 1994; 124:144-50. PubMed
  • Bianchi DW, Bernfield M, Nathan DG. A revived opportunity for fetal research. Nature 1993; 363:12. PubMed
  • Guinan EC, Lee YS, Lopez KD, Kohler S, Oette DH, Bruno E, Kozakewich H, Nathan DG, Hoffman R. Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 1993; 81:1691-8. PubMed
  • Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood 1993; 81:1109-23. PubMed
  • Davies K, TePas EC, Nathan DG, Mathey-Prevot B. Interleukin-3 expression by activated T cells involves an inducible, T-cell-specific factor and an octamer binding protein. Blood 1993; 81:928-34. PubMed
  • Jubinsky PT, Nathan DG, Wilson DJ, Sieff CA. A low-affinity human granulocyte-macrophage colony-stimulating factor/murine erythropoietin hybrid receptor functions in murine cell lines. Blood 1993; 81:587-91. PubMed
  • Sieff CA, Yokoyama CT, Zsebo KM, Trammell J, Andersen JW, Nathan DG, Williams DA. The production of steel factor mRNA in Diamond-Blackfan anaemia long-term cultures and interactions of steel factor with erythropoietin and interleukin-3. Br J Haematol 1992; 82:640-7. PubMed
  • McDonagh KT, Dover GJ, Donahue RE, Nathan DG, Agricola B, Byrne E, Nienhuis AW. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp Hematol 1992; 20:1156-64. PubMed
  • Liboi E, Jubinsky P, Andrews NC, Nathan DG, Mathey-Prevot B. Enhanced expression of interleukin-3 and granulocyte-macrophage colony-stimulating factor receptor subunits in murine hematopoietic cells stimulated with hematopoietic growth factors. Blood 1992; 80:1183-9. PubMed
  • Crosier KE, Wong GG, Mathey-Prevot B, Nathan DG, Sieff CA. A functional isoform of the human granulocyte/macrophage colony-stimulating factor receptor has an unusual cytoplasmic domain. Proc Natl Acad Sci U S A 1991; 88:7744-8. PubMed
Hide